Abstract
Methods Seventy nine patients with juvenile onset SLE (64 females, 15 males, median age 21.0 years, range 14.5 to 39.0 years) treated at the Transition Clinic of Rheumatology Section from January 2008 to December 2010 were evaluated. In all subjects DXA at the lumbar spine, pQCT at radius and phalangeal osteosonography were performed at the same time. The data obtained were compared with 80 ageand sexmatched healthy subjects. All patients at evaluation were receiving Hydroxychloroquine, 50/79 low dose steroids, 35 mycophenolate mofetil, 10 azathioprine and 2/69 had received four infusions of Rituximab. Results At DXA examination, all JSLE patients showed a reduced BMD SDS (p <0.001), total trabecular density, strain strength index, muscle area, cortical bone area, fat area (p <0.001) in comparison to controls. However, we did not find any significant statistical differences regarding AD-SoS and QUS. A significant correlation was found between BMD SDS, disease activity (SLEDAI score), dose and duration of corticosteroids therapy (p <0.001).
Highlights
There are few prospective data on bone mass and quality in a large number of patients with Juvenile Systemic Lupus Erythematosus (JSLE)
Aim To assess the prevalence and to identify the main predictors of reduced BMD and bone quality in a cross-sectional evaluation of a large cohort of SLE patients with disease onset before 18 years
In all subjects dual energy X-ray absorptiometry (DXA) at the lumbar spine, peripheral quantitative computed tomography (pQCT) at radius and phalangeal osteosonography were performed at the same time
Summary
Cross-sectional evaluation of bone mass in young adults with Juvenile Onset Systemic Lupus Erythematosus: the role of bone mass determinants in a large cohort of patients. Falcini Fernanda1*, Stagi Stefano, Cavalli Loredana, Capannini Serena, Masi Laura, Ceri Lorenzo, Denaro Valentina, Matucci Cerinic Marco, Brandi Maria Luisa. From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. 14-18 September 2011
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.